EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting together cholinesterases and serotonin reuptake against Alzheimer’s disease

Thomas Guiselin iD, Cédric Lecoutey iD, Christophe Rochais iD, Patrick Dallemagne iD

Journal of Pharmacy and Pharmacology · 2025

DOI: 10.1093/jpp/rgaf041 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Thomas Guiselin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Université de Caen Normandie, CERMN UR4258, Normandie Univ, 14000 Caen, France. Hauptthemen laut MEDLINE: Alzheimer Disease, Selective Serotonin Reuptake Inhibitors, Cholinesterase Inhibitors, Cholinesterases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 116 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by cognitive decline and memory loss, with limited therapeutic options. Traditional treatments primarily focus on acetylcholinesterase inhibitors (AChEIs), which aim to increase acetylcholine levels in the brain, and selective serotonin reuptake inhibitors (SSRIs), which modulate serotonin levels. However, these treatments often provide only modest symptom relief. This review explores the potential benefits of combined targeting of cholinesterases and serotonin reuptake as a novel therapeutic strategy for AD. We discuss the pathophysiological role of acetylcholine and serotonin in AD, highlighting their impact on cognitive function, mood regulation, and neuroplasticity. By targeting both cholinergic and serotonergic systems, this dual approach may offer synergistic effects, improving cognitive function, reducing neuropsychiatric symptoms, and enhancing neuroprotective mechanisms. The review also examines preclinical and clinical studies investigating the efficacy of combination therapies and outlines the challenges and opportunities in their development. Ultimately, this combined targeting approach holds promise for providing more effective and comprehensive treatment options for AD, addressing both cognitive and behavioural symptoms associated with the disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseSelective Serotonin Reuptake InhibitorsCholinesterase InhibitorsCholinesterasesHumansAnimalsCognitionSerotoninAcetylcholineDrug Therapy, Combination

Stichwörter der Autor:innen

Alzheimer’s diseasecholinesterasescognitive declinecombination therapyserotonin reuptake inhibitors

Substanzen

Selective Serotonin Reuptake InhibitorsCholinesterase InhibitorsSerotoninAcetylcholineCholinesterases

Autor:innen und Institutionen

  • Université de Caen Normandie, CERMN UR4258, Normandie Univ, 14000 Caen, France.

ORCID-Profile: Thomas Guiselin, Cédric Lecoutey, Christophe Rochais, Patrick Dallemagne

Zitieren

APA

Guiselin, T., Lecoutey, C., Rochais, C., & Dallemagne, P. (2025). Targeting together cholinesterases and serotonin reuptake against Alzheimer’s disease. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf041

Vancouver

Guiselin T, Lecoutey C, Rochais C, Dallemagne P. Targeting together cholinesterases and serotonin reuptake against Alzheimer’s disease. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgaf041

BibTeX
@article{Guiselin2025,
  author = {Guiselin, Thomas and Lecoutey, Cédric and Rochais, Christophe and Dallemagne, Patrick},
  title = {Targeting together cholinesterases and serotonin reuptake against Alzheimer’s disease},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2025},
  doi = {10.1093/jpp/rgaf041}
}
Kostenlos starten →